Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Glaucoma Pipeline Drugs Analysis Report Overview
Glaucoma represents a group of optic neuropathies characterized by the progressive degeneration of retinal ganglion cells (RGCs). It is the leading cause of irreversible vision loss worldwide. The Glaucoma marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in Glaucoma therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for glaucoma.
Leading Marketed Drugs for Glaucoma
Some of the leading marketed drugs for glaucoma are aflibercept, brimonidine, bimatoprost, latanoprost, travoprost, tafluprost, levobunolol, brinzolamide, dorzolamide, and timolol.
Glaucoma Marketed Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for glaucoma marketed drugs are receptor agonist, receptor antagonist, enzyme inhibitor, enzyme replacement, cell and cell organelle inhibitor, enzyme activator, ligand inhibitor, transporter inhibitor, ion channel blocker, and ion channel activator.
Glaucoma Marketed Drugs Analysis, by Mechanism of Action
For more MoA insights into the Glaucoma marketed drugs, download a free report sample
Glaucoma Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for glaucoma marketed drugs are injection, oral, and topical.
Glaucoma Marketed Drugs Analysis, by Routes of Administration
For more RoA insights into the Glaucoma marketed drugs, download a free report sample
Glaucoma Marketed Drugs Segmentation by Molecule Type
Most of the marketed drugs for glaucoma are small molecules. Biologics is another significant molecule type in the marketed drugs for glaucoma.
Glaucoma Marketed Drugs Analysis, by Molecule type
For more molecule type insights into the Glaucoma marketed drugs, download a free report sample
Leading Pipeline Drugs for Glaucoma
Some of the leading pipeline drugs of glaucoma are netarsudil mesylate, ripasudil hydrochloride hydrate, latanoprost, PH-011, PH-012, netarsudil mesylate, (tafluprost + timolol maleate), latanoprost, (bimatoprost + timolol), and (latanoprost + netarsudil).
Glaucoma Pipeline Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for glaucoma pipeline drugs are receptor agonist, enzyme inhibitor, receptor antagonist, protein & peptide inhibitor, enzyme activator, ion channel blocker, biological factor inhibitor, protein & peptide activator, biological factor activator, and ion channel activator.
Glaucoma Pipeline Drugs Analysis, by Mechanisms of Action
For more MoA insights into the Glaucoma pipeline drugs market, download a free report sample
Glaucoma Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for glaucoma pipeline drugs are topical, injection, oral, and inhalational.
Glaucoma Pipeline Drugs Analysis, by Routes of Administration
For more routes of administration insights for Glaucoma pipeline drugs market, download a free report sample
Glaucoma Pipeline Drugs Segmentation by Molecule Type
The glaucoma pipeline comprises mostly of small molecules. Biologics and oligonucleotide are the other significant molecule types in the pipeline drugs for glaucoma.
Glaucoma Pipeline Drugs Analysis, by Molecule Types
For more molecule type insights into the Glaucoma pipeline drugs market, download a free report sample
Top Sponsors in the Glaucoma Marketed and Pipeline Drugs Market
Some of the top sponsors in the glaucoma marketed and pipeline drugs market are Santen Pharmaceutical Co Ltd, Aerie Pharmaceuticals Inc, Alcon Inc, Allergan Ltd, Sun Yat-sen University.
Glaucoma Marketed Drugs Report Overview
Key Mechanisms of Action | Receptor Agonist, Receptor Antagonist, Enzyme Inhibitor, Enzyme Replacement, Cell and Cell Organelle Inhibitor, Enzyme Activator, Ligand Inhibitor, Transporter Inhibitor, Ion Channel Blocker, and Ion Channel Activator |
Key Routes of Administration | Topical, Oral, and Injection |
Key Molecule Types | Small Molecule and Biologics |
Top Sponsors (Marketed and
Pipeline Drugs) |
Santen Pharmaceutical Co Ltd, Aerie Pharmaceuticals Inc, Alcon Inc, Allergan Ltd, Sun Yat-sen University |
Glaucoma Pipeline Drugs Market Report Overview
Key Mechanisms of Action | Receptor Agonist, Enzyme Inhibitor, Receptor Antagonist, Protein & Peptide Inhibitor, Enzyme Activator, Ion Channel Blocker, Biological Factor Inhibitor, Protein & Peptide Activator, Biological Factor Activator, and Ion Channel Activator |
Key Routes of Administration | Topical, Injection, Oral, and Inhalational |
Key Molecule Types | Small Molecule, Biologic, and Oligonucleotide |
Scope
GlobalData’s Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Glaucoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for Glaucoma marketed drugs?
The key mechanisms of action for Glaucoma marketed drugs are receptor agonist, receptor antagonist, enzyme inhibitor, enzyme replacement, cell and cell organelle inhibitor, enzyme activator, ligand inhibitor, transporter inhibitor, ion channel blocker, and ion channel activator.
-
What are the key routes of administration for Glaucoma marketed drugs?
The key routes of administration for Glaucoma marketed drugs are topical, oral, and injection.
-
What are the key molecule types for Glaucoma marketed drugs?
The key molecule types for Glaucoma marketed drugs are small molecule and biologic.
-
What are the key mechanisms of action for Glaucoma pipeline drugs?
The key mechanisms of action in the Glaucoma pipeline drugs market are receptor agonist, enzyme inhibitor, receptor antagonist, protein & peptide inhibitor, enzyme activator, ion channel blocker, biological factor inhibitor, protein & peptide activator, biological factor activator, and ion channel activator.
-
What are the key routes of administration for Glaucoma pipeline drugs?
The key routes of administration in the Glaucoma pipeline drugs market are topical, injection, oral, and inhalational.
-
What are the key molecule types for Glaucoma pipeline drugs?
The key molecule types in the Glaucoma pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Who are the top sponsors for the Glaucoma marketed and pipeline drugs market?
Some of the top sponsors for the Glaucoma marketed and pipeline drugs market are Santen Pharmaceutical Co Ltd, Aerie Pharmaceuticals Inc, Alcon Inc, Allergan Ltd, Sun Yat-sen University
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.